Modality
Degrader
MOA
STINGag
Target
C5
Pathway
Neuroinflam
EoEAMLGA
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
Oct 2019
→ Aug 2031
Phase 2Current
NCT04930921
638 pts·GA
2019-10→TBD·Active
NCT07666191
764 pts·GA
2020-02→2031-08·Not yet recruiting
1,402 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-265.4y awayPh2 Data· GA
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Active
P2
Not yet…
Catalysts
Ph2 Data
2031-08-26 · 5.4y away
GA
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04930921 | Phase 2 | GA | Active | 638 | PFS |
| NCT07666191 | Phase 2 | GA | Not yet recr... | 764 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-5389 | Roche | Preclinical | RET | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 |